Dr. Lal PathLabs surged 4.76% to Rs 1,230.50 at 15:15 IST on BSE after the company said it is in the process of completing the due diligence and legal documentation for the acquisition of Delta Ria & Pathology.
The announcement was made during market hours today, 21 November 2016.Meanwhile, the S&P BSE Sensex was down 389.78 points or 1.49% at 25,760.46.
On BSE, so far 33,000 shares were traded in the counter as against average daily volume of 11,000 shares in the past two weeks. The stock hit a high of Rs 1,278.55 so far during the day, which is a record high for the counter. The stock hit a low of Rs 1,175 so far during the day. The stock had hit a record low of Rs 696.50 on 20 January 2016.
Dr. Lal PathLabs said it expects to complete the acquisition of Delta Ria & Pathology (DRPPL) by 31 March 2017. The company had in May 2016, announced the acquisition of DRPPL.
Dr. Lal PathLabs' consolidated net profit jumped 748.3% to Rs 52.51 crore on 21.52% growth in total income from operations to Rs 262.17 crore in Q2 September 2016 over Q2 September 2015.
Dr. Lal PathLabs is a provider of diagnostics and related healthcare tests and services in India. Customers include individual patients, companies and institutions, healthcare providers as well as hospital and clinical labs.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content